Search results
Author(s):
Giuseppe Galati
,
Pierre Sabouret
,
Olga Germanova
,
et al
Added:
2 years ago
Author(s):
Juan Tamargo
Added:
3 years ago
Type 2 diabetes (T2D) remains a major cardiovascular (CV) risk factor1–5 and it confers an approximately two- to threefold fold excess risk for coronary heart disease, including MI, stroke and heart failure (HF) in patients with and in patients without established cardiovascular disease (CVD).1,6–8 The prevalence of T2D among patients with HF is as high as 40–45% and that of HF in patients with…
View more
Author(s):
Felipe Martínez
Added:
2 years ago
Author(s):
Tariq Ahmad
,
Ralph J Riello
,
Silvio Inzucchi
Added:
2 years ago
Author(s):
Maki Komiyama
,
Koji Hasegawa
Added:
3 years ago
Type 2 diabetes is a major risk factor for the development of cardiovascular disease (CVD) such as MI, and cerebrovascular incidents such as stroke. A substantial body of evidence has indicated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular disease such as retinopathy and nephropathy.
Nevertheless, whether strict blood glucose…
View more
Author(s):
Jack Wei Chieh Tan
,
David Sim
,
Junya Ako
,
et al
Added:
2 years ago
Author(s):
Muthiah Vaduganathan
Added:
3 years ago
In this video, Dr Muthiah Vaduganathan (Brigham and Women's Hospital, Boston, US) shares the findings from the EMPA-REG OUTCOME trial. The goal of the trial was to assess the cardiovascular (CV) safety of empagliflozin, a sodium–glucose cotransporter 2 (SGLT-2) inhibitor, in patients with type 2 diabetes mellitus (T2DM) at high risk for CV events.
Questions:
1. What is the background of…
View more
Inflammation in Diabetes
Author(s):
Sotirios Tsalamandris
,
Alexios S Antonopoulos
,
Evangelos Oikonomou
,
et al
Added:
3 years ago
Article
Author(s):
Aarti Thakkar
,
Anandita Agarwala
,
Erin D Michos
Added:
2 years ago